Other posts you might like:

News

Life Sciences Ontario Celebrates Excellence and Innovation in Life Sciences with 2026 Awards Announcement

TORONTO, ON – January 15th, 2026 - Life Sciences Ontario (LSO) proudly announces the recipients of the 2026 LSO Awards, ...
News, Opinion

Life Sciences Ontario (LSO) welcomes Budget 2025: Building Canada Strong and the federal government’s continued investment in innovation, research, and the life sciences sector

Ontario’s life sciences sector contributes $58.1 billion to Ontario’s GDP, generates $8.8 billion in government revenue,...
Press Release

Catalyzing Ontario’s Life Sciences Economy: Read Life Sciences Ontario’s New Report

TORONTO, ON – [25 June 2025]: Life Sciences Ontario (LSO), in partnership with Shift Health, has just released a new rep...
Announcement

LSO President and CEO Jason Field Receives King Charles III Coronation Medal

Recognition highlights leadership in advancing Ontario's life sciences sector Life Sciences Ontario (LSO) is proud to...
June 13, 2019
News

A Response to the Advisory Council's report on the Implementation of National Pharmacare and PMPRB

A Response to the Advisory Council’s report on the Implementation of National Pharmacare and PMPRB

Last September, Life Sciences Ontario (LSO) made a submission to the Advisory Council on the Implementation of National Pharmacare, led by Eric Hoskins. Our quick review of the Hoskins Council report that was tabled yesterday raises a few alarm bells that I think our members, and all Canadians, should be aware of.

LSO made three recommendations to the Council: (a) don’t reinvent – renovate to fill gaps; (b) be efficient and make best use of resources; and (c) encourage innovation and investment to help patients, our health system and our economy. The final report from Hoskins falls short on all three points.

To read the full letter click here.

Author: ElizabethVoss